Chi Van Dang, MD, PhD, director of the Abramson Cancer Center, is quoted in a Philadelphia Inquirer article detailing the center's plans to begin doing genetic tests later this year on cancer cells of all patients with diseases including melanoma, acute myelogenous leukemia, and brain and lung cancer. The results will reveal which patients could benefit from new drugs that work only for those with certain mutations. They will also prevent others from experiencing side effects from drugs that likely won't help them. Dang will discuss this "revolution" in cancer care today at Cancer Support Community of Philadelphia conference.
See more at Philadelphia Inquirer